SCHEDULE 13G
Amendment No. 7
Neurocrine Biosciences Incorporated
Common Stock
Cusip #64125C109
Cusip #64125C109
Item 1: Reporting Person - FMR LLC
Item 4: Delaware
Item 5: 672,750
Item 6: 0
Item 7: 3,182,865
Item 8: 0
Item 9: 3,182,865
Item 11: 8.378%
Item 12: HC
Cusip #64125C109
Item 1: Reporting Person - Edward C. Johnson 3d
Item 4: United States of America
Item 5: 0
Item 6: 0
Item 7: 3,182,865
Item 8: 0
Item 9: 3,182,865
Item 11: 8.378%
Item 12: IN
SCHEDULE 13G - TO BE INCLUDED IN
STATEMENTS
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)
This Amendment to Schedule 13G filed by FMR LLC amends
the statement on Schedule 13G previously filed by FMR
Corp., the predecessor of FMR LLC.
Item 1(a). Name of Issuer:
Neurocrine Biosciences Incorporated
Item 1(b). Name of Issuer's Principal Executive Offices:
10555 Science Center Drive
San Diego, CA 92121
Item 2(a). Name of Person Filing:
FMR LLC
Item 2(b). Address or Principal Business Office or, if None,
Residence:
82 Devonshire Street, Boston,
Massachusetts 02109
Item 2(c). Citizenship:
Not applicable
Item 2(d). Title of Class of Securities:
Common Stock
Item 2(e). CUSIP Number:
64125C109
Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b)
and the person filing, FMR LLC, is a parent holding company
in accordance with Section 240.13d-1(b)(ii)(G). (Note: See
Item 7).
Item 4. Ownership
(a) Amount Beneficially Owned: 3,182,865
(b) Percent of Class: 8.378%
(c) Number of shares as to which such
person has:
(i) sole power to vote or to direct
the vote: 672,750
(ii) shared power to vote or to
direct the vote: 0
(iii) sole power to dispose or to
direct the disposition of: 3,182,865
(iv) shared power to dispose or to
direct the disposition of: 0
Item 5. Ownership of Five Percent or Less of a Class.
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another
Person.
Various persons have the right to receive or the power to
direct the receipt of dividends from, or the proceeds from the
sale of, the Common Stock of Neurocrine Biosciences
Incorporated. No one person's interest in the Common Stock
of Neurocrine Biosciences Incorporated is more than five
percent of the total outstanding Common Stock.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent
Holding Company.
See attached Exhibit A.
Item 8. Identification and Classification of Members of
the Group.
Not applicable. See attached Exhibit A.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certification.
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired in the
ordinary course of business and were not acquired for the
purpose of and do not have the effect of changing or
influencing the control of the issuer of such securities and
were not acquired in connection with or as a participant in any
transaction having such purpose or effect.
Signature
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement
is true, complete and correct.
October 09, 2007
Date
/s/John McGinty
Signature
John McGinty
Duly authorized under Power of Attorney dated May 18, 2007,
by Eric D. Roiter by and on behalf of FMR LLC and its direct
and indirect subsidiaries
SCHEDULE 13G - TO BE INCLUDED IN
STATEMENTS
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)
Pursuant to the instructions in Item 7 of Schedule 13G,
Fidelity Management & Research Company ("Fidelity"), 82
Devonshire Street, Boston, Massachusetts 02109, a wholly-
owned subsidiary of FMR LLC and an investment adviser
registered under Section 203 of the Investment Advisers Act
of 1940, is the beneficial owner of 3,182,865 shares or 8.378%
of the Common Stock outstanding of Neurocrine Biosciences
Incorporated ("the Company") as a result of acting as
investment adviser to various investment companies registered
under Section 8 of the Investment Company Act of 1940.
Edward C. Johnson 3d and FMR LLC, through its
control of Fidelity, and the funds each has sole power to
dispose of the 3,182,865 shares owned by the Funds.
Members of the family of Edward C. Johnson 3d,
Chairman of FMR LLC, are the predominant owners, directly
or through trusts, of Series B voting common shares of FMR
LLC, representing 49% of the voting power of FMR LLC.
The Johnson family group and all other Series B shareholders
have entered into a shareholders' voting agreement under
which all Series B voting common shares will be voted in
accordance with the majority vote of Series B voting common
shares. Accordingly, through their ownership of voting
common shares and the execution of the shareholders' voting
agreement, members of the Johnson family may be deemed,
under the Investment Company Act of 1940, to form a
controlling group with respect to FMR LLC.
Neither FMR LLC nor Edward C. Johnson 3d,
Chairman of FMR LLC, has the sole power to vote or direct
the voting of the shares owned directly by the Fidelity Funds,
which power resides with the Funds' Boards of Trustees.
Fidelity carries out the voting of the shares under written
guidelines established by the Funds' Boards of Trustees.
SCHEDULE 13G - TO BE INCLUDED IN
STATEMENTS
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)
RULE 13d-1(f)(1) AGREEMENT
The undersigned persons, on October 09, 2007, agree
and consent to the joint filing on their behalf of this Schedule
13G in connection with their beneficial ownership of the
Common Stock of Neurocrine Biosciences Incorporated at
September 30, 2007.
FMR LLC
By /s/ John McGinty
John McGinty
Duly authorized under Power of Attorney dated May
18, 2007, by Eric D. Roiter by and on behalf of FMR LLC and
its direct and indirect subsidiaries
Edward C. Johnson 3d
By /s/ John McGinty
John McGinty
Duly authorized under Power of Attorney dated May
18, 2007, by Eric D. Roiter by and on behalf of Edward C.
Johnson 3d
Fidelity Management & Research Company
By /s/ John McGinty
John McGinty
Duly authorized under Power of Attorney dated May
18, 2007, by Eric D. Roiter Senior V.P. and General Counsel